Dr. Natalie Dean is an assistant professor in the Department of Biostatistics at the University of Florida specializing in infectious disease epidemiology and study design. She is principal investigator on a National Institutes of Health (NIH) R01 grant to develop and evaluate innovative trial and observational study designs for assessing the efficacy of vaccines targeting emerging pathogens. She previously worked on the design and analysis of a Phase 3 Ebola vaccine trial in Guinea that used a novel ring vaccination strategy. Her current research focuses on design features adapted to the outbreak setting. These include responsive study designs that recruit participants only in areas where transmission is observed. This also includes multi-outbreak designs implemented under a single master protocol. Finally, she studies the statistical properties of the test negative design and its suitability in outbreaks. Dr. Dean received her doctorate in biostatistics from Harvard University in 2014 and performed her postdoctoral work with Dr. Ira Longini at the University of Florida. She has also worked as a statistical consultant for the World Health Organization’s (WHO) HIV Department in their HIV drug resistance group.
Natalie E. Dean, PhD Presentations
June 18, 2020 at 12:30 PM - 1:45 PM
It is getting more difficult for some vaccines to be licensed on the basis of traditional randomized controlled trial demonstrations of efficacy against disease. This session will cover the latest thinking about clinical trial designs and approaches to demonstrate vaccine effectiveness to support licensure (including use of biomarkers predictive of protection, human challenge studies, and real word evidence).